Sort
4,870 grants matching “glp 1”
Cyclic Orynotides for Systemic MDR Candidiasis
$983,348Dat Quang Tran · Oryn Therapeutics, Llc · R44 · FY2022 · AI
A Bullet Proof vascular graft to prevent dialysis access cannulation injury
$982,927Joseph Knight · Innavasc Medical, Inc. · R44 · FY2017 · DK
Targeted Bone Regeneration via Activation of Resident Stem Cells
$982,825Tracey Rogers · National Center For Advancing Translational Sciences · ZIA · FY2025 · TR
Spectroscopic Localization of Breast Cancer
$982,695David A. Benaron · Spectros Corporation · R44 · FY2009 · CA
Preclinical development of PPCM vaginal contraceptive to submit IND.
$982,217Mary B Weitzel · Yaso Therapeutics Inc · R44 · FY2018 · HD
Enabling rapid and effective stroke thrombectomy procedures from a Transradial approach: Combining introducer sheath, guide catheter, and distal access catheter into a single device.
$982,021Jared Hutar · Piraeus Medical, Inc. · R44 · FY2024 · NS
Factor XII Inhibitor for Surface Initiated Thrombosis
$981,954Erik Ian Tucker · Aronora, Inc. · R44 · FY2021 · HL
Definitive Studies For Use Of Galantamine As A Pre-Treatment Countermeasure Again
$981,654Bill Basinger · Countervail Corporation · R44 · FY2011 · NS
Neuroprotective role of GLP-1 receptor agonists
$981,407Nigel H. Greig · National Institute On Aging · ZIA · FY2017 · AG
Advancing a Glioma Immunotherapy
$981,388Dwaine Franklin Emerich · In Cytu, Inc. · R44 · FY2013 · NS
Optimization of novel pyranopyridine efflux pump inhibitors
$981,076Timothy J Opperman · Microbiotix, Inc · R44 · FY2020 · AI
Isovolumetric Multimodal Venous Thrombectomy System
$981,043Stacey Liekweg · Caeli Vascular, Llc · R42 · FY2021 · HL
A Novel Xenon Delivery Platform for Cerebroprotection During Stroke
$980,725Keith Booher · Zymo Research Corporation · R42 · FY2025 · NS
Novel HBV Therapeutic with Potential for Treatment of Drug-Resistant Infection
$980,003Andrea Cuconati · Pharmabridge, Inc. · R44 · FY2012 · AI
Novel HBV Therapeutic with Potential for Treatment of Drug-Resistant Infection
$979,945Simon Baugh · Pharmabridge, Inc. · R44 · FY2013 · AI
A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance
$979,534Neil A Fanger · Virtici, Llc · R44 · FY2022 · AI
Subcutaneous Acute Ischemia Monitor
$979,104Dave Lawrence Keenan · Angel Medical Systems, Inc. · R44 · FY2014 · HL
A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance
$978,755Neil A Fanger · Virtici, Llc · R44 · FY2023 · AI
TP508: A New Drug for Mitigating Lethal Effects of Radiatin Exposure
$978,663Laurie E Sower · Chrysalis Biotherapeutics, Inc. · R44 · FY2014 · AI
Production of a Hydrogel-based Mucosal Sealant for Gastrointestinal Bleeding Prevention
$977,992Gonzalo Munoz Taboada · Biodevek Inc · R44 · FY2024 · DK
Pre-Clinical HPV16 Antiviral Compound Development
$977,163Christopher Fisher · Nanovir, Llc. · R42 · FY2009 · AI
Glutide for Ending Methamphetamine
$977,129Phillip O Coffin · Public Health Foundation Enterprises · UG3 · FY2025 · DA
Long-acting Growth Hormone for Treating HIV-Associated Adipose Redistribution Syn
$976,501George Norbert Cox · Bolder Biotechnology, Inc. · R44 · FY2008 · AI
Enhancing Dental and Craniomaxillofacial Surgery Outcomes with Cost-Effective and Scalable Animal-Free Amino Acid-Based Membranes for Guided Bone Regeneration
$976,000Sherif Soliman · Matregenix · R44 · FY2025 · DE
Preclinical Development of Oxy200 for the Treatment of Osteoporosis
$975,009Frank Stappenbeck · Max Biopharma, Inc. · R44 · FY2019 · AG